Go Pro
→ The dollar just broke (From Porter & Company) (Ad)tc pixel Free SCLXW Stock Alerts

Scilex (SCLXW) Competitors

Scilex logo
$0.18 +0.01 (+4.81%)
Closing price 08/14/2026 03:46 PM Eastern
Extended Trading
$0.18 +0.00 (+1.09%)
As of 08/14/2026 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SCLXW vs. SXTPW, BFRIW, CALA, CINGW, and CLVR

Should you buy Scilex stock or one of its competitors? Scilex's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Calithera Biosciences (CALA), Cingulate (CINGW), and Clever Leaves (CLVR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Scilex compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Scilex (NASDAQ:SCLXW) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A
Scilex$33.86MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Scilex N/A N/A N/A

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Scilex. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Scilex. 60 Degrees Pharmaceuticals' average media sentiment score of 1.93 beat Scilex's score of 1.89 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Scilex Very Positive

Summary

60 Degrees Pharmaceuticals beats Scilex on 2 of the 3 factors compared between the two stocks.

How does Scilex compare to Biofrontera?

Scilex (NASDAQ:SCLXW) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scilex$33.86MN/AN/AN/AN/A
Biofrontera$43.20MN/AN/AN/AN/A

In the previous week, Biofrontera had 2 more articles in the media than Scilex. MarketBeat recorded 3 mentions for Biofrontera and 1 mentions for Scilex. Scilex's average media sentiment score of 1.89 beat Biofrontera's score of 0.96 indicating that Scilex is being referred to more favorably in the media.

Company Overall Sentiment
Scilex Very Positive
Biofrontera Positive

Company Net Margins Return on Equity Return on Assets
ScilexN/A N/A N/A
Biofrontera N/A N/A N/A

Summary

Biofrontera beats Scilex on 2 of the 3 factors compared between the two stocks.

How does Scilex compare to Calithera Biosciences?

Scilex (NASDAQ:SCLXW) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Scilex had 1 more articles in the media than Calithera Biosciences. MarketBeat recorded 1 mentions for Scilex and 0 mentions for Calithera Biosciences. Scilex's average media sentiment score of 1.89 beat Calithera Biosciences' score of 0.00 indicating that Scilex is being referred to more favorably in the media.

Company Overall Sentiment
Scilex Very Positive
Calithera Biosciences Neutral

Company Net Margins Return on Equity Return on Assets
ScilexN/A N/A N/A
Calithera Biosciences N/A N/A N/A

Scilex has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scilex$33.86MN/AN/AN/AN/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Summary

Scilex beats Calithera Biosciences on 3 of the 3 factors compared between the two stocks.

How does Scilex compare to Cingulate?

Cingulate (NASDAQ:CINGW) and Scilex (NASDAQ:SCLXW) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

In the previous week, Cingulate had 1 more articles in the media than Scilex. MarketBeat recorded 2 mentions for Cingulate and 1 mentions for Scilex. Scilex's average media sentiment score of 1.89 beat Cingulate's score of 1.44 indicating that Scilex is being referred to more favorably in the news media.

Company Overall Sentiment
Cingulate Positive
Scilex Very Positive

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
Scilex N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
Scilex$33.86MN/AN/AN/AN/A

Summary

Scilex beats Cingulate on 2 of the 3 factors compared between the two stocks.

How does Scilex compare to Clever Leaves?

Scilex (NASDAQ:SCLXW) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Scilex has higher revenue and earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scilex$33.86MN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

In the previous week, Scilex had 1 more articles in the media than Clever Leaves. MarketBeat recorded 1 mentions for Scilex and 0 mentions for Clever Leaves. Scilex's average media sentiment score of 1.89 beat Clever Leaves' score of 0.00 indicating that Scilex is being referred to more favorably in the media.

Company Overall Sentiment
Scilex Very Positive
Clever Leaves Neutral

Company Net Margins Return on Equity Return on Assets
ScilexN/A N/A N/A
Clever Leaves N/A N/A N/A

Summary

Scilex beats Clever Leaves on 3 of the 5 factors compared between the two stocks.

Get Scilex News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCLXW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCLXW vs. The Competition

Export
MetricScilexPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$11.79B$7.03B$13.07B
Dividend YieldN/A2.70%2.57%10.64%
P/E RatioN/A779.99271.5425.40
Price / SalesN/A948.84673.88125.76
Price / CashN/A89.0475.7053.27
Price / BookN/A11.6012.926.21
Net IncomeN/A$2.77B$3.45B$347.71M
7 Day PerformanceN/A0.14%1.16%1.08%
1 Month Performance-8.50%0.65%2.17%1.87%
1 Year Performance-60.30%145.68%62.38%20.79%

Scilex Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCLXW
Scilex
N/A$0.18
+4.8%		N/A-60.3%$0.00$33.86MN/A105
SXTPW
60 Degrees Pharmaceuticals
N/A$0.03
-15.5%		N/AN/A$0.00$1.00MN/A2
BFRIW
Biofrontera
N/A$0.02
-21.3%		N/A-75.2%$0.00$43.20MN/A70
CALA
Calithera Biosciences
N/AN/AN/AN/A$0.00N/AN/A60
CINGW
Cingulate
N/A$0.01
+2.5%		N/A-84.4%$0.00N/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SCLXW) was last updated on 8/16/2026 by MarketBeat.com Staff.
From Our Partners
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your 10X AI demo is starting…
Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investme...
TradeSmith | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Why acquisitions are reshaping the gold mining sector right now
Gold major acquisitions have repriced junior miners overnight, with past deals delivering gains from 40% to 1,...
Golden Portfolio | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
What is Trump’s decade-long obsession?
No president has moved markets like Trump, adding and erasing trillions in value seemingly at will. Analyst...
Brownstone Research | Sponsoredtc pixel